Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
Therapeutics and Clinical Risk Management Aug 18, 2017
Leonetti A, et al. – The clinicians explored the efficacy of a combination lenvatinib plus everolimus for the treatment of metastatic renal cell carcinoma (mRCC). Outcomes indicated that the combination therapy with lenvatinib plus everolimus might be a promising option for second–line treatment of mRCC patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
